Media

페이지 정보

본문

Topline Results of Domestic PSP Phase 2 Clinical Trial

to Be Presented at the Symposium

GemVax & KAEL Co., Ltd. (hereinafter GemVax, 082270) announced on the 25th that it will participate as a signature sponsor in the international research symposium "Neuro2024," focusing on progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).

At the conference, GemVax will introduce the topline results of its domestic Phase 2 clinical trial for PSP and will hold a related briefing session.

"Neuro2024" is an annual academic conference that brings together leading neuroscience experts from around the globe to present their research findings on PSP and CBD. Organized by CurePSP, this year’s event will take place in Toronto, Canada, on October 24th and 25th.

As a signature and main sponsor of the conference, GemVax will present the results of its PSP clinical trial and engage in discussions with global thought leaders on neurodegenerative diseases. The company also plans to foster connections through active exchanges with PSP patients and their families.

CurePSP is a New York-based non-profit organization founded in 1990 that raises awareness and supports research for PSP, CBD, and multiple system atrophy (MSA). The organization engages in various activities, including community building, providing information to patients and families, and funding research initiatives while facilitating collaborations among experts.

PSP is an atypical Parkinson's syndrome characterized by symptoms similar to Parkinson's disease but marked by rapid progression and no definitive cure. Key symptoms include gait disturbances, postural instability, speech disorders, and eye movement abnormalities, with the underlying cause of the disease still unidentified.

Currently, GemVax is conducting the first domestic Phase 2 clinical trial for PSP. In February this year, the Ministry of Food and Drug Safety (MFDS) designated the new drug as a "development stage orphan drug".

In preparation for a global PSP clinical trial, GemVax has also received FDA approval for its Phase 2 clinical trial plan in the United States.

댓글목록

등록된 댓글이 없습니다.